



# 18th International Myeloma Workshop

**SEPTEMBER 8-11, VIENNA AUSTRIA**

**PRELIMINARY  
PROGRAM**



# Wednesday, September 8th

09:00-10:00

## OPENING SESSION

Opening Ceremonies and Welcome to IMW18	Organizers of 18th IMW
Historical perspectives: Milestones in Myeloma	Robert Kyle
IMS President Address	Nikhil Munshi

## PLENARY SESSIONS

10:00-11:15

### Precursor Conditions

*Session Chairs: Mario Boccardo/Sigurdur Kristinsson*

Genomic evolution - germinal B cell to MGUS/SMM/MM	Brian Walker
Role of the immune Microenvironment in the journey to MGUS/SMM/MM	Madhav Dhodapkar
Molecular Timing of Initiation	Niels Weinhold
Risk factors for MGUS/SMM progression	Vincent Rajkumar
Management of Smoldering Myeloma	Marivi Mateos
Should we screen for precursor conditions?	Irene Ghobrial

11:15-12:30

### Molecular dissection of myeloma

*Session Chairs: Leif Bergsagel/Masood Shamma*

Clonal diversity in Myeloma	Mehmet Samur
Transcriptome	Jill Corre
Epigenomic	Wee Joo Chng
Microbiome	Leif Bergsagel
Proteomics	Arun Wiita
Metabolomics	Rafael Fonseca

12:30-13:30

## EXPOSITION AND LUNCH

## PLENARY SESSION

13:30-14:30

### Multiple Myeloma Diagnosis

*Session Chairs: Sonja Zweegman/P. Joy Ho*

Diagnostic criteria and work-up in 2021	Shaji Kumar
How should we define standard and high risk MM in 2022?	Herve Avet-Loiseau
Role of imaging in diagnosis and response assessment	Elena Zamagni
Circulating tumor cells and tumor DNA for response assessment	Bruno Paiva
Mass-spec to monitor the treatment response	Dave Murray
Assessment of patient frailty and functional status	Alessandra Larocca

14:30-15:15

## IMS AWARDS

Bart Barlogie/Ken Anderson Young Investigator Award Presentation
Waldenstrom Award Presentation and Lecture

15:15-15:45

## EXPOSITION AND BREAK

---

15:45-16:45

### INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI

Welcome and Introduction	Tom Martin (Chair)
A critical part of the puzzle: Should MRD guide adaptive treatment?	Fredrik Schjesvold
Assembling the evidence: The pros and cons of MRD as a surrogate endpoint	Tom Martin
The role of MRD negativity in HR NDMM: a new piece to overcoming poor prognosis?	Martin Kaiser
Panel discussion and concluding remarks	All faculty

---

16:45-17:45

### HOT TOPICS IN MYELOMA

#### In 2021, what is the unmet need in Myeloma?

*Session Moderators: Nikhil Munshi/Jesús San Miguel*

*Panelists: TBC*

I square effort updates and future directions	Brian Durie
---	-------------

---

17:45-19:15

### WELCOME RECEPTION IN EXPOSITION AREA

---

## Thursday, September 9th

08:00-09:00

### MEET THE EXPERTS

Extramedullary disease	Cyrille Touzeau
Plasma cell leukemia	Artur Jurczynszyn/Ravi Vij
Management of Monoclonal gammopathy of renal significance	Javier de la Rubia/ Moshe Gatt
Management of Monoclonal gammopathy of clinical significance	Laura Rosiñol/ Ajay Nooka
Special forms of MM: macrofocal, non-secretory MM	Stathis Kastritis/ Jacob Laubach
Management of LC Amyloidosis	Vaishali Sanchorawala/ Eli Muchtar
Management of Waldeström's Macroglobulinemia	Ramón García Sanz/ Prashant Kapoor
Management of POEMS	Angela Dispenzieri/ Anita D'Souza
Allogeneic Stem Cell Transplantation in MM	Amrita Krishnan/ Charlotte Pawlyn

---

08:00-09:00

### CAREER DEVELOPMENT WORKSHOP

#### Writing successful grants

Suzanne Lentzsch/  
Diane Jelinek

---

09:00-09:30

## OPENING SESSION

### Novel therapies for myeloma

Kenneth Anderson

---

09:30-10:30

## PLENARY SESSION

### Newly diagnosed Multiple Myeloma: Current Treatment Approaches

*Session Chairs: David Siegel*

Treatment of Newly Diagnosed Myeloma Transplant Eligible: what is the optimal induction? Philippe Moreau

ASCT in NDMM transplant eligible Michele Cavo

Consolidation Strategies for MM Pieter Sonneveld

Maintenance Strategies for MM Hartmut Goldschmidt

Treatment of Newly Diagnosed Myeloma Non-Transplant Eligible Thierry Facon

---

10:30-11:45

## ORAL ABSTRACT SESSIONS

*Session Chairs:*

*Lugui Qiu/Ed Stadtmauer*

- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts

*Session Chairs:*

*Paola Neri/Dharminder Chauhan/Niklas Zojer*

- Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
- 

11:45-12:45

## PLENARY SESSION

### Management of relapsed/refractory MM patients

*Session Chairs: Meral Beksac/Gösta Gahrton*

Approach to first relapse Meletios-Athanassios Dimopoulos

Management of triple refractory patients Bob Orłowski

Role of immunotherapies for relapsed MM, when and which? Saad Usmani

Personalized treatment of relapsed MM: genomics? Marc Raab

---

12:45-13:45

## EXPOSITION AND LUNCH

---

13:45-15:15

## INDUSTRY SYMPOSIUM SUPPORTED BY JANSSEN

The role of non-cellular modern therapeutics in the treatment of myeloma Ajai Chari (Chair)

Evolving treatment strategies in multiply-relapsed multiple myeloma Gordon Cook

Clinical results from BCMA targeted T-cell redirectors Niels van de Donk

Early clinical results of alternative targets for bispecifics and next generation T-cell redirectors Ajai Chari

Implications for clinical practice with these new agents Hareth Nahi

Panel discussion and concluding remarks All faculty

---

15:15-16:30

## ORAL ABSTRACT SESSIONS

*Session Chairs:*  
Natalie Callander/Merav Leiba

- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts

*Session Chairs:*  
Enrique Ocio/Annemeik Brojil

- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts

---

16:30-17:00

## EXPOSITION AND BREAK

---

17:00-18:00

## INDUSTRY SYMPOSIUM SUPPORTED BY GSK

Welcome and Introduction	Mohamad Mohty (Chair)
Mechanism of action of anti-BCMA ADCs for the treatment of multiple myeloma	Katja Weisel
Positioning BCMA-targeted ADCs in the relapsed/refractory multiple myeloma setting	Suzanne Trudel
Management of adverse events caused by BCMA-targeted ADC therapy	Rakesh Popat
Panel discussion and concluding remarks	All faculty

---

18:00-19:00

## POSTER SESSION

# Friday, September 10th

08:00-09:00

## MEET THE EXPERTS

Covid-19 and MM	Wenming Chen/ Sarah Holstein
Vaccination and prophylaxis in Myeloma	Laurent Garderet
Management of cellular therapy-related toxicities	Jesus Berdeja/Krina Patel
Bone disease control in Myeloma	Matthew Drake
Management of MM patients with renal impairment	Ruben Niesvizky
Which is the ideal patient to be referred for CAR-T vs bi-specific vs ADC?	Melissa Alsina/ Sham Mailankody
Racial disparity and monoclonal gammopathies	Craig Cole

---

08:00-09:00

## CAREER DEVELOPMENT WORKSHOP

### Developing your first clinical trial

Simon Harrison/  
Jean-Luc Harousseau

---

09:00-09:30

## OPENING SESSION

### Future of myeloma treatment

Jesus San Miguel

---



09:30-10:30

## IMS/EHA SYMPOSIUM

### Immune Therapies: A game changer for Hematological Malignancies

*Chairs: TBC*

CART

TBC

Other Immune Approaches

TBC

---

10:30-11:45

## ORAL ABSTRACT SESSIONS

*Session Chairs:*

*Michael O'Dwyer*

- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts

*Session Chairs:*

*Ruth De Tute/Aurore Perrot/Tomas Jelinek*

- Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
- 

## PLENARY SESSION

11:45-12:45

### Other Plasma Cell Disorders

*Session Chairs: Giampolo Merlini/Jorge Castillo*

Current strategies for AL patients

Giovanni Palladini

What are the novel approaches in WM?

Steve Treon

Monoclonal gammopathy of clinical significance

Joan Blade

Monoclonal gammopathy of renal significance

Nelson Leung

---

12:45-13:45

## EXPOSITION, POSTER SESSION AND LUNCH

13:45-15:15

## INDUSTRY SYMPOSIUM SUPPORTED BY BMS

The next generation Immunotherapy for myeloma

Noopur Raje (Chair)

Early Clinical evidence for CAR-T Cell Therapy in MM

Nina Shah

Future of Cellular Therapies in MM

Sham Mailankody

E3 ligase as therapeutic target

Nizar Bahlis

Early clinical promise of targeting E3 ligase

Sagar Lonial

Strategies for immune combination therapies

Noopur Raje

---

15:15-16:30

## ORAL ABSTRACT SESSIONS

*Session Chairs:*

*Jens Hillengass/Angelo Maiolino*

- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts

*Session Chairs:*

*Constantine Mitsiades/Virgina Abello*

- Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
  - Selected from Submitted Abstracts
- 

16:30-17:00

## EXPOSITION AND BREAK

17:00-18:00

## INDUSTRY SYMPOSIUM SUPPORTED BY AMGEN

Welcome and Introduction	Keith Stewart, Chair
Defining Refractories in MM: The Scientific Perspective	Kwee Yong
Defining Refractories in MM: The clinical Perspective	Peter Voorhees
Optimal Treatment Sequencing for Malignant MM in Early Relapse	Keith Stewart
Panel discussion and concluding remarks	All faculty

18:00-19:00

## HOT TOPICS IN MYELOMA

### **Covid-19 in MM: what we have learnt?**

*Session Moderators: Karthik Ramasamy/Douglas Joshua*

What have we learned?	Evangelos Terpos
Panelists	Joaquín Martínez, Pankaj Malhotra, Heinz Ludwig, Juan Du, Dorotea Fantl, Jakub Radocha

20:00-23:00

## IMS CULTURAL CELEBRATION AND AWARDS PRESENTATION

# Saturday, September 11, 2021

08:00-09:00

## MEET THE EXPERTS

Animal models for myeloma	Karin Vanderkerkin/ Marta Chesi
Genomic techniques	Mark Bustoros/ Ruben Carrasco
Approaches to proteomic analysis	Saloman Manier/Naomi Puig
Primary sample processing and enrichment techniques	Jonathan Keats/Daniel Auclair
Single cell approaches	Manoj Bhasin/Jens Lohr
Assessing the immune system	Hearn Cho/Tax Kourelis
Metabolomics techniques in MM	Malathy Shanmugam/ Wilson Gonsalves
ChIP in Myeloma	Adam Sperling

08:00-09:00

## CAREER DEVELOPMENT WORKSHOP

<b>Setting up your laboratory research program</b>	Rodger Tiedeman/ Larry Boise
--	---------------------------------

09:00-10:00

## INDUSTRY SYMPOSIUM SUPPORTED BY ONCOPEPTIDES

Welcome and Introduction	Graham Jackson (Chair)
Impact of patient and disease factors on choice to therapy in RRMM - how far have we come today?	Sikander Ailawadhi
Current treatment options in RRMM - which challenges remain?	Paula Rodriguez
What is coming on the horizon for RRMM - are the remaining challenges resolved?	Paul Richardson
Panel discussion and concluding remarks	All faculty

10:00-11:15

## ORAL ABSTRACT SESSIONS

*Session Chairs:*

*Jae Hoon Lee/*

*Elizabet Manasanach*

- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts

*Session Chairs:*

*Mariateresa Fulciniti/Nicolo Bolli/*

*Maria-Theresa Krauth*

- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts
- Selected from Submitted Abstracts

11:15-13:15

## PLENARY SESSION

### Great Debates in Myeloma

*Moderators: Ludwig/Goldschmidt/Einsele/Hajek*

Transplant for every NDMM transplant eligible? MRD-guided therapy?	Morie Gertz/Sergio Giralto Sundar Jagannath/ Ola Landgren
Stratification based on genomics ready for primetime?	Gareth Morgan/Faith Davies
Which is the best immune approach to replace ASCT? CAR-T vs Bispecific antibodies	Hermann Einsele/ Parameswaran Hari
Can we give our patient treatment free intervals?	Luciano Costa/ Phil McCarthy
The role of alkylator in MM	Donna Reece/Jeff Wolf

13:15-13:45

## LUNCH

13:45-14:45

## PLENARY SESSIONS

### Supportive care management

*Session Chairs: Andrezj Jakubowiak/Rafat Abonour*

Management of renal failure	Jean-Paul Fermand
Approaches to bone health	Evangelos Terpos
Management of infections	Michel Delforge
Toxicity management	TBC
Vaccinations in myeloma including covid-19	Heinz Ludwig



14:45-15:45

## **Immune Therapies**

*Session Chairs: Qing Yi/Ivan Borello*

Mechanism of resistance to CAR-T cells and bispecifics	Yi Lin
How to improve the efficacy of CAR-T cells and bi-specifics?	Michael Hudecek
Allo-CAR-T cels	Roman Hajek
CAR- NK cells	Adam Cohen
Vaccination Therapies for Myeloma	David Avigan

---

15:45-16:45

## **Clinical Trials in Progress**

*Moderators: William Bensinger/Raymond Comenzo*

North America	Jonathan Kaufman
Europe	Xavier Leleu
South America	Vania Hungria
Asia	Jeffrey Huang
Australia	Hang Quach

---

16:45-16:55

## **WELCOME TO 19TH IMW**

Organizers of 19th IMW

---

16:55-17:00

## **CLOSING COMMENTS**

Organizers of 18th IMW

Ludwig/Goldschmidt/  
Einsele/Hajek

The IMS gratefully acknowledges  
the following organizations for  
their sponsorship of the 18th  
International Myeloma Workshop:

TITANIUM LEVEL



PLATINUM LEVEL



SILVER LEVEL

